Galapagos

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The good news keeps rolling in for this Belgian pharma.

Here's Why Galapagos NV Stock Rose 13.4% in June

Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.

Galapagos Ends Enrollment in Osteoarthritis Study Before Time

Galapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2019 Results - Earnings Call Transcript

Gilead Sciences

Galapagos' experimental rheumatoid arthritis drug hit the mark in two late-stage studies last month.

Why Galapagos NV Stock Bolted Higher in March

Gilead Sciences and its partner Galapagos have done well to obtain positive results from a late-stage study in patients with rheumatoid arthritis (RA) using their drug filgotinib.

Gilead Has A Shot To Regain Investor Confidence With Inflammatory Disorder Drug Filgotinib

The biotech reported nothing but good news from multiple clinical trials of its promising immunology drug.

Why Galapagos Stock Is Crushing It Today

Celgene

Zealand Pharma

These three healthcare gems have the full attention of our team of experts.

3  Top Biotech Stocks to Buy in March

Axsome Therapeutics

Clinical trial readouts expected before the end of March will put shares of these drugmakers on the move.

2 Biotech Stocks  With Major Incoming Catalysts

News for Galapagos Stock (GLPG)